A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03124368 |
Recruitment Status :
Completed
First Posted : April 21, 2017
Results First Posted : July 13, 2021
Last Update Posted : November 4, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
C3 Glomerulonephritis Dense Deposit Disease C3 Glomerulopathy Immune Complex Mediated Membranoproliferative Glomerulonephritis Membranoproliferative Glomerulonephritis Types I, II, and III | Drug: Danicopan | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 6 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Participants With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) |
Actual Study Start Date : | August 9, 2017 |
Actual Primary Completion Date : | December 21, 2018 |
Actual Study Completion Date : | January 9, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Group 1: Danicopan 100 mg TID (Sentinel)
All participants received 100 milligrams (mg) of danicopan three times per day (TID) during the Treatment Period.
|
Drug: Danicopan
Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).
Other Names:
|
Experimental: Group 2: Danicopan up to 200 mg TID
All participants received not more than 200 mg of danicopan TID depending on the available safety, pharmacokinetic, and pharmacodynamic data from Group 1 (Sentinel) during the Treatment Period.
|
Drug: Danicopan
Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).
Other Names:
|
- Change From Baseline In Serum C3 Complement Protein (C3) Levels On Day 15 [ Time Frame: Baseline, Day 15 ]
Serum C3 levels were measured by conventional Roche immunoturbidimetric assay method.
Change from Baseline = Serum C3 levels on Day 15 - Baseline Serum C3 levels
- Change From Baseline In Plasma Intact C3 Level On Day 15 [ Time Frame: Baseline, Day 15 ]Plasma Intact C3 level were measured by a novel multiplex assay method. Change from Baseline = Plasma Intact C3 levels on Day 15 - Baseline Plasma Intact C3 levels
- Change From Baseline In Total Complement Classical Pathway (CP) Activity On Day 14 [ Time Frame: Baseline, Day 14 ]
CP activity was measured in serum by the DiaSorin Complement Activation Enzyme (CAE) functional immunoassay method, which measures terminal complement complex formation following activation. Results are expressed in CAE units which are calculated relative to previously established CAE activity of a positive control serum.
Change from Baseline = Total Complement CP Activity on Day 14 - Baseline Total Complement CP Activity
- Change From Baseline In Total Complement Alternative Pathway (AP) Functional Activity (AP Wieslab) On Day 15 [ Time Frame: Baseline, Day 15 ]
AP functional activity was measured in serum by the Wieslab functional immunoassay method, which measures terminal complement complex (TCC) formation following AP-specific activation. Results are expressed as percent TCC production relative to a positive control serum.
Change from Baseline = Total Complement AP Functional Activity on Day 15 - Baseline Total Complement AP Functional Activity
- Time To Achieving Peak Serum C3 Levels [ Time Frame: From The First Day Of Dosing through Day 14 ]Serial serum samples were collected on Days 1, 7, and 14.
- Number Of Participants With Serious Adverse Events (SAEs), Grade 3 And Grade 4 Treatment-emergent Adverse Events (TEAEs), And Adverse Events (AEs) Leading To Discontinuation [ Time Frame: Up to Day 49 ]An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. The intensity of an AE was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Adverse Event Severity Grading Table. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
- Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve From Time Of Administration To 8 Hours Postdose (AUC0-8) [ Time Frame: Days 1 and 7 ]Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.
- PK: Maximum Plasma Concentration (Cmax) [ Time Frame: Days 1 and 7 ]Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.
- PK: Time To Maximum Concentration (Tmax) [ Time Frame: Days 1 and 7 ]Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.
- Change From Baseline In Bb Fragment Of Complement Factor B (Bb) At Day 15 [ Time Frame: Baseline, Day 15 ]
Plasma Bb was measured by enzyme-linked immunosorbent assay (ELISA).
Change from Baseline = Complement Bb on Day 15 - Baseline
- Change From Baseline In Soluble Terminal Complement Complex (sC5b-9) At Day 15 [ Time Frame: Baseline, Day 15 ]
Plasma sC5b-9 was measured by ELISA.
Change from Baseline = sC5b-9 on Day 15 - Baseline sC5b-9

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 65 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Must have had clinical diagnosis of C3G (C3 glomerulonephritis or dense deposit disease, the 2 types of C3G) or idiopathic IC-MPGN by renal biopsy for at least 3 months prior to dosing, with the pathologic diagnosis verified by a review of the renal biopsy by the study central pathologist
- C3 must have been <50% of the lower limit of normal
- C4 complement protein (C4) must have been >90% of the lower limit of normal
- Must have been willing to comply with study-specific vaccination requirements for Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis strains A, C, W, and Y
- Negative pregnancy test for females prior to dosing and throughout the study
Key Exclusion Criteria:
- History of a major organ transplant (for example, heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant. Individuals receiving renal replacement therapy were also excluded
- Evidence of monoclonal gammopathy of unclear significance, infections, malignancy, autoimmune diseases, or other conditions to which C3G or IC-MPGN may have been secondary
- Estimated glomerular filtration rate (using Modification of Diet in Renal Disease equation) <45 milliliters/minute/1.73 square meters at the time of Screening or at any time over the preceding 4 weeks
- Receipt of eculizumab at any dose or interval within the past 75 days prior to dosing
- Use of tacrolimus or cyclosporine within 2 weeks of the first dose of danicopan
- History of febrile illness, a body temperature >38°Celsius, or other evidence of a clinically significant active infection, within 14 days prior to study drug administration
- History of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection
- Females who were pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration or participants with a female partner who was pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03124368
Australia | |
Clinical Trial Site | |
Melbourne, Australia | |
Belgium | |
Clinical Trial Site | |
Antwerpen, Belgium | |
Netherlands | |
Clinical Trial Site | |
Leiden, Netherlands |
Documents provided by Alexion Pharmaceuticals:
Responsible Party: | Alexion Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT03124368 |
Other Study ID Numbers: |
ACH471-201 2016-003525-42 ( EudraCT Number ) |
First Posted: | April 21, 2017 Key Record Dates |
Results First Posted: | July 13, 2021 |
Last Update Posted: | November 4, 2021 |
Last Verified: | October 2021 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
factor D FD alternative pathway complement mediated disease idiopathic MPGN MPGN Type I MPGN Type II MPGN Type III Primary MPGN |
MCGN Mesangiocapillary Glomerulonephritis C3 Glomerulopathy C3G Membranoproliferative Glomerulonephritis C3GN Dense Deposit Disease DDD |
Glomerulonephritis Glomerulonephritis, Membranoproliferative Nephritis |
Kidney Diseases Urologic Diseases Immune System Diseases |